PDCD1 and melanoma: The first U.S. Food and Drug Administration (FDA) approval of a CTLA‐4 antibody (ipilimumab) in 2011 was followed by the approval of two PD‐1 antibodies (pembrolizumab and nivolumab) in 2014, all exclusively for treatment of advanced-stage melanoma [2–5].